1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Cancer Drug News 15 FEBRUARY 2016

Cancer Drug News 15 FEBRUARY 2016

  • February 2016
  • -
  • Espicom Business Intelligence
  • -
  • 12 pages

Industry Trend Analysis - Ownership Of Digital Reputation Crucial With Growing Compassionate Use Demand
Industry Brief - Amgen's Kyprolis In Combination Now Available In UK To Treat Relapsed MM
Industry Brief - Incyte To Discontinue Phase III Study Of Jakafi Plus Capecitabine In MPC
Industry Trend Analysis - European Alimta Threats Will Place Further Pressure On Lilly
Industry Brief - IDMC Recommends Stopping Alecensa Phase III Trial Early After Positive Outcomes
Industry Brief - Ferring Initiates Phase IIIb Trial Of Degarelix ADT Therapy In Advanced PCA And CVD
Industry Trend Analysis - Combination Approach Increases Commercial Scope For Small Oncolytic Immunotherapy Developers
Industry Brief - Lannett Gains Temozolomide Approval
Industry Brief - Enrolment Begins In Melphalan/HDS System Phase III Trial In Hepatic Dominant OM
Industry Brief - Adaptimmune's NY-ESO T-Cell Therapy Granted Breakthrough Therapy Designation
Industry Brief - Tollys Secures Rights To Riboxx' Apoxxim For TLR3-Positive Cancers
Industry Brief - Epizyme's Tazemetostat Gains Orphan Drug Designation For MRTs
Industry Brief - EMA Accepts Sandoz' Biosimilar Pegfilgrastim Submission
Industry Trend Analysis - Expanded Injectable Approval Will Not Maintain Emend's Market Position
Industry Brief - OncoGenex To Reduce Workforce

Table Of Contents

Cancer Drug News 15 FEBRUARY 2016

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorde ...

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung ...

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025 Summary Myelofibrosis (MF) is a rare blood disorder, which is characterized by bone marrow fibrosis. Currently, there is ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.